PBAC decision on Olaparib (Lynparza)
Community Affairs Committee’s Inquiry into the availability of new, innovative and specialist cancer drugs in Australia
In February 2015, Ovarian Cancer Australia lodged a submission into the availability of new, innovative and specialist cancer drugs in Australia. Our Director of Research and Advocacy, Dr Katherine Nielsen, was witness at the senate hearing in April and upon request by the committee, made further written recommendations in May 2015. Our submission was based on consultations with women diagnosed with ovarian cancer and their carers, consultations with other cancer support organisations and internal expertise in the field of pharmaceutical development and reimbursement. OCA made recommendations for improving transparency on the Pharmaceutical Benefits Advisory Committee decision making and streamlining processes.
Therapeutic Goods Administration Discussion paper on the Orphan drugs program released for public comment
Ovarian Cancer Australia participated in a consumer-led panel by the Therapeutic Goods Administration in February 2015. Ovarian Cancer Australia’s response to the TGA’s discussion paper included recommendations for improving the Orphan drugs program and was lodged in June 2015.
The Standing Committee on Health: Inquiry into Chronic Disease Prevention and Management in Primary Health Care
Ovarian Cancer Australia is a formal member of the Lymphoedema Action Alliance (LAA) which made a strong submission to the Standing Committee in August 2015.
Medical Services Advisory Committee’s Protocol Advisory Sub-Committee (PASC): Application 1380
PASC is looking into germline BRCA mutation testing to determine eligibility for Olaparib maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer, including fallopian tube or primary peritoneal cancer, with high grade serous features or a high grade serous component.
Ovarian Cancer Australia provided a written response and supporting documentation for the BRCA testing protocol in November 2014. Our submission was informed by a previously conducted qualitative consumer survey and through conducting a focus group involving women with high-grade serous cancer.
Pharmaceutical Benefits Advisory Committee public submission regarding the use of bevacizumab in advanced epithelial ovarian, fallopian tube or primary peritoneal cancer
Ovarian Cancer Australia made a written submission in November 2013. Our submission was informed through a qualitative study whereby in depth interviews with women with advanced ovarian cancer who were disease-free after their initial treatment and women who had experienced one or more recurrences. The interview process was designed to explore the value that women place on the end points that are commonly reported as the basis for decisions about the efficacy of therapeutic agents – progression-free survival and overall survival.